Skip to main content

Table 3 Summary of AEs during treatment with riociguat

From: Riociguat in patients with chronic thromboembolic pulmonary hypertension: results from an early access study

AE, n (%)

Full analysis set

(n = 300)

Switched patients

(n = 84)a

Treatment-naïve

patients

(n = 216)

Any AE

273 (91)

76 (90)

197 (91)

Drug-related AEs

178 (59)

53 (63)

125 (58)

Serious AEs

89 (30)

22 (26)

67 (31)

Drug-related serious AEs

19 (6)

4 (5)

15 (7)

AEs leading to discontinuation of study medication

14 (5)

5 (6)

9 (4)

Deaths

5 (2)

0

5 (2)

  1. AE adverse event, PDE5 phosphodiesterase type 5, ERA endothelin receptor antagonist
  2. aPatients who previously received an ERA, prostacyclin, and/or PDE5 inhibitor, and who stopped this treatment before starting riociguat